Compare BLNK & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BLNK | ADCT |
|---|---|---|
| Founded | 2009 | 2011 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 86.2M | 136.1M |
| IPO Year | 2008 | 2019 |
| Metric | BLNK | ADCT |
|---|---|---|
| Price | $0.55 | $1.22 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 4 |
| Target Price | $2.33 | ★ $7.75 |
| AVG Volume (30 Days) | 1.1M | ★ 1.8M |
| Earning Date | 05-08-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 61.22 | 30.86 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $126,197,000.00 | $81,357,000.00 |
| Revenue This Year | $5.71 | N/A |
| Revenue Next Year | $19.65 | $66.49 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 14.85 |
| 52 Week Low | $0.45 | $0.78 |
| 52 Week High | $2.65 | $4.98 |
| Indicator | BLNK | ADCT |
|---|---|---|
| Relative Strength Index (RSI) | 46.96 | 57.00 |
| Support Level | $0.53 | $1.03 |
| Resistance Level | $0.62 | $1.45 |
| Average True Range (ATR) | 0.03 | 0.08 |
| MACD | 0.00 | 0.04 |
| Stochastic Oscillator | 43.88 | 77.40 |
Blink Charging Co is an owner, operator, and provider of electric vehicle (EV) charging services. The company offers both residential and commercial EV charging equipment, enabling EV drivers to easily recharge at various location types. The Blink's principal line of products and services is its Blink EV charging networks, Blink EV charging equipment, and other EV-related services. The Blink Network is a proprietary, cloud-based system that operates, maintains, and manages Blink charging stations and handles the associated charging data, back-end operations, and payment processing. The Blink Network provides fleets, property owners, managers, parking companies, and state and municipal entities, among other types of commercial customers, with cloud-based services.
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. Additionally, the company's development pipeline comprises LOTIS-2, LOTIS-5, LOTIS-7, and ADCT-241, being developed as potential therapies for different cancer diseases. Geographically, the firm generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).